163 related articles for article (PubMed ID: 37343207)
1. Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
Castro-Alonso FJ; Beas-Lozano E; Remolina-Bonilla YA; Flaig TW; Bourlon MT
Oncology (Williston Park); 2023 Jun; 37(6):256-261. PubMed ID: 37343207
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
[TBL] [Abstract][Full Text] [Related]
3. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
Cathomas R; Lorch A; Bruins HM; Compérat EM; Cowan NC; Efstathiou JA; Fietkau R; Gakis G; Hernández V; Espinós EL; Neuzillet Y; Ribal MJ; Rouanne M; Thalmann GN; van der Heijden AG; Veskimäe E; Alfred Witjes J; Milowsky MI;
Eur Urol; 2022 Jan; 81(1):95-103. PubMed ID: 34742583
[TBL] [Abstract][Full Text] [Related]
4. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
Gross-Goupil M; Domblides C; Lefort F; Ravaud A
Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
[TBL] [Abstract][Full Text] [Related]
5. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
7. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
8. Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K; Bellmunt J
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
[No Abstract] [Full Text] [Related]
9. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
[TBL] [Abstract][Full Text] [Related]
10. Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Siefker-Radtke AO; Loriot Y
Am J Health Syst Pharm; 2022 May; 79(11):824-825. PubMed ID: 35147178
[No Abstract] [Full Text] [Related]
11. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
[TBL] [Abstract][Full Text] [Related]
12. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
Loriot Y; O'Hagan A; Siefker-Radtke AO
Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptors across urothelial carcinoma landscape.
Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
[TBL] [Abstract][Full Text] [Related]
14. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Kojima Y; Takahi Y; Ichimaru N; Okumi M; Takahara S; Nonomura N
BMC Res Notes; 2015 Feb; 8():25. PubMed ID: 25648269
[TBL] [Abstract][Full Text] [Related]
17. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
18. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
[TBL] [Abstract][Full Text] [Related]
19. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
Mathew Thomas V; Grivas P; Agarwal N
Med; 2024 Feb; 5(2):109-111. PubMed ID: 38340704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
